Analysis of Tumor Suppressor Gene p53 in Chicken Lymphoblastoid Tumor Cell Lines and Field Tumors

Journal of Veterinary Medical Science

Volumn 60, Issue 8, 1998, Pages 923-929

  Takagi, Michihiro ^a   Ohashi, Kazuhiko ^a   Morimura, Toshifumi ^a   Sugimoto, Chihiro ^a   Onuma, Misao ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Marek's disease; p53; RT PCR; Transformation

Indexed keywords

GALLUS GALLUS;

PRIMER DNA; PROTEIN P53; VIRUS DNA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; ANIMAL DISEASE; ARTICLE; BIRD DISEASE; CELL CULTURE; CHEMISTRY; CHICKEN; EXON; GENE DELETION; GENETIC TRANSCRIPTION; GENETICS; LYMPHOMA; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; RETICULOENDOTHELIOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; CHICKENS; DNA PRIMERS; DNA, VIRAL; EXONS; GENES, P53; LYMPHOMA; MAREK DISEASE; MOLECULAR SEQUENCE DATA; MUTATION; POINT MUTATION; POULTRY DISEASES; RETICULOENDOTHELIOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; SEQUENCE DELETION; SEQUENCE HOMOLOGY, AMINO ACID; SEQUENCE HOMOLOGY, NUCLEIC ACID; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032135309     PISSN: 09167250     EISSN: None     Source Type: Journal    
DOI: 10.1292/jvms.60.923     Document Type: Article

References (34)

1. Akiyama, Y. and Kato, S. 1974. Two cell lines from lymphomas of Marek's disease. Biken J. 17 105-116.
2. Brunovskis, P., Qian, Z., Li, D., Lee, L. F. and Kung, H-J. 1996. Functional analysis of the MDV basic-leucine zipper product, meq. pp. 265-270 In: Current Research on Marek's Disease (Silva, R F., Cheng, H.H., Coussens P.M., Lee, L.F. and Velicer, L.F. eds.), American Association of Avian Pathologists, Kennett Square.
3. Calnek, B.W., Murthy, K.K. and Schat, K.A. 1978. Establishment of Marek's disease lymphoblastoid cell lines from transplantable versus primary lymphoma. Int. J. Cancer 21: 100-107.
4. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W. and Vogelstein, B. 1992, Definition of a consensus binding site for p53. Nature Genetics 1: 45-49.
5. Finlay, C.A., Hinds, P. W. and Levine, A. J. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093.
6. Hihara, H., Shimizu, T. and Yamamoto, H. 1974. Establishment of tumor cell lines cultured from chickens with avian lymphoid leukosis. Natl. Inst. Anim. Health Q. 14: 163-173.
7. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. 1991. p53 mutations in human cancers. Science 253: 49-53.
8. Hupp, T.R., Meek, D. W., Midgley, C. A. and Lane, D.P. 1992. Regulation of the specific DNA binding function of p53. Cell 71: 875-886.
9. Ikuta, K., Nakajima, K., Kanamori, A., Maotani, K., Mah, J.S., Ueda, S., Kato, S., Yoshida, M., Nii, S., Naito, M., Nishida-Umehara, C., Sasaki, M. and Hirai, K. 1985, Establishment and characterization of a T-lymphoblastoid cell line MDCC-MTB1 derived from chicken lymphocytes infected in vitro with Marek's disease virus serotype I. Int. J. Cancer 39: 514-520.
10. Kastan, M.B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B. and Fornace, A. J. Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.
11. Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W. and Vogelstein, B. 1992. Oncogenic form of p53 inhibit p53-regulated gene expression. Science 256: 827-830.
12. Komori, H., Ishiguro, N., Horiuchi, M., Shinagawa, M. and Aida, Y. 1996. Predominant p53 mutations in enzootic bovine leukemic cell lines. Vet. Immunol. Immunopathol. 52: 53-63.
13. Kulesz-Martin, M.F., Lisafeld, B., Huang, H., Kisiel, N. D. and Lee L. 1994. Endogenous p53 protein generated from wild type alternatively spliced p53 RNA in mouse epidermal cells. Mol. Cell. Biol. 14: 1698-1708.
14. Lane, D.P. 1992. p53, guardian of the genome. Nature (Lond.) 358: 15-16.
15. Lane, D.P. and Crawford, L.V. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature (Lond.) 278: 261-263.
16. Mayr, B., Heczko, U., Schellander, K., Schleger, W. and Reifinger, M. 1994. Sequence of an exon of the canine p53 gene-mutation in a papilloma. Br. Vet. J. 150: 81-84.
17. Meek, D. W. 1994. Post-translational modification of p53. Cancer Biol. 5: 203-210.
18. Nazerian, K., Stephens, E. A., Sharma, J. M., Lee, L. F., Gailitis, M. and Witter, R. L. 1976. A nonproducer T lymphoblastoid cell line from Marek's disease transplantable tumor (JMV). Avian Dis. 21: 69-76.
19. Nigro, J. M., Baker, S. J., Presinger, A. C. Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C C. and Vogelstein, B. 1989. p53 gene mutations occur in diverse human tumor types. Nature (Lond.) 342: 705-708.
20. Powell, P. C., Payne, L. N., Frazier, J. A. and Rennie, M. 1974. T lymphoblastoid cell lines from Marek's disease lymphomas. Nature (Lond.) 251: 79-80.
21. Sarnow, P., Ho, Y. S., Williams, J. and Levine, A. J. 1982. Adenovirus E16-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54kd cellular protein in transformed cells. Cell 28: 387-394.
22. Sasaki, T., Koyama, H., Yoshikawa, H. and Sasahara, J. 1981. Establishment of tumor cell lines cultured from chick embryos and chickens inoculated with oncogenic reticuloendotheliosis virus, p. 170. In: Proceedings of the 92nd Meeting of the Japanese Society for Veterinary Science.
23. Schat, K. A. 1987. Marek's disease a model for protection against herpesvirus-induced tumors. Cancer Surv. 6: 1-37.
24. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. and Howley, P. M. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
25. Shaulsky, G., Ben-Ze'ev, A. and Rotter, V. 1990. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 5: 1707-1711.
26. Soussi, T., Caron de Fromentel, C. and May, P. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 945-952.
27. Sturzbecher, H.-W., Brain, R., Addison, C., Rudge, K., Remm, M., Grimaldi, M. and Keenan. E. 1992. A C-terminal Éø-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7: 1513-1523.
28. Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A. and Gu, J-R. 1994. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. U.S.A. 91: 2230-2234.
29. Wang, Y., Reed, M., Wang, P., Stenger, J. E., Mayr, G., Anderson, M. E., Schwedes, J. F and Tegtmeyer, P. 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7: 2575-2586.
30. Xie, Q., Anderson, A. S. and Morgan, R. W. 1996. Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC-MSB1 MDV-transformed lymphoblastoid cells. J.Virol. 70: 1125-1131.
31. Yamaguchi, S., Kawamura, H., Matsuda, H. and Kato, S. 1979. Establishment of Marek's disease lymphoblastoid cell lines from chickens with BABK of B blood groups. Biken J. 22: 35-40.
32. Yew, P. R. and Berk, A. J. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (Lond.) 357: 82-85.
33. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C. and Wahl, G. M. 1992. Wild-type p51 restores cell cycle control and inhibits gene amplification in cell with mutant p53 alleles. Cell 70: 937-948.
34. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. and Oren, M. 1991. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond.) 352: 345-347.